SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial
SeaStar Medical activates 14th site for NEUTRALIZE-AKI trial, evaluating SCD device for AKI patients on CRRT. 70 of 200 planned subjects enrolled, with interim analysis expected mid-2025. SCD targets hyperinflammation, with potential U.S. market of $4.7B-$6.3B for AKI treatment.
Highlighted Terms
Related News
SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial
SeaStar Medical activates 14th site for NEUTRALIZE-AKI trial, evaluating SCD device for AKI patients on CRRT. 70 of 200 planned subjects enrolled, with interim analysis expected mid-2025. SCD targets hyperinflammation, with potential U.S. market of $4.7B-$6.3B for AKI treatment.